Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations
News
The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations. The priority review status ... Read more